RxDoctor Payments Data

Yevgeniya Bagdasarova, PA

Physician Assistant · Fresno, CANPI 1699701102

Payments from drug & device makers

$3,427in general payments, 2019–2025

Across 165 payments — averaging $20.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$934
  • Lilly USA, LLC$672
  • AbbVie$322
  • Novo Nordisk$282
  • Boehringer Ingelheim$271
  • Sumitomo Pharma America, Inc.$105
  • plus $842 from 20 others

What the payments were for

  • Food & beverage$3,427100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,427 in reported general payments places this provider in the 85th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$25,620
Medicare patients
105
Services billed
577

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide151$139,713
MounjaroTirzepatide64$64,620
LinzessLinaclotide68$56,684
TrulicityDulaglutide57$55,293
JardianceEmpagliflozin37$50,972
JanuviaSitagliptin Phosphate49$46,547
ZenpepLipase/Protease/Amylase12$43,441
EliquisApixaban33$38,830
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog83$34,699
TradjentaLinagliptin39$30,489
JanumetSitagliptin Phos/Metformin Hcl23$25,599
SynjardyEmpagliflozin/Metformin Hcl32$23,271
FarxigaDapagliflozin Propanediol24$19,580
Fiasp FlextouchInsulin Aspart (Niacinamide)26$18,374
Synjardy XrEmpagliflozin/Metformin Hcl17$15,660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$282$139,713151 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy, Synjardy Xr$271$120,391125 claims
Lilly USA, LLCMounjaro, Trulicity$672$119,913121 claims
AbbVieLinzess, Synthroid$322$60,331104 claims
Aimmune Therapeutics, Inc.Zenpep$87$43,44112 claims
GSKTrelegy Ellipta$17$5,79711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →